Navigation Links
Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
Date:7/1/2010

rkets the following brands under co-promotion agreements: AndroGel®, with Solvay Pharmaceuticals, Inc., and Femring®, with Warner Chilcott Limited.  The Watson Brand pipeline portfolio includes a number of products, including URACYST®, under development for cystitis; and four novel new contraceptives.  All other trademarks are property of their respective owners.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. For example, any statements in this press release concerning the future growth of Watson's product portfolio, the future success of CRINONE® and PROCHIEVE®, the anticipated closing of the acquisition, the anticipated benefits of the acquisition, future approvals or other events related to CRINONE® and PROCHIEVE® and business plans are forward-looking statements. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting the acquisition or Watson's business. These factors include, among others, the risk of not completing the acquisition for any reason, including as result of third party intervention; successful integration of the Columbia products and product rights; the impact of competitive products and pricing; timel
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , August 28, 2014 ... "DNA diagnostics Market (products, applications, techniques, end users ... Growth and Forecast, 2013 - 2020," indicates that ... billion by 2020 registering a CAGR of 9.8% ... accurate diagnosis and cost effectiveness over alternative diagnostic ...
(Date:8/28/2014)... 28, 2014  Seres Health, a clinical-stage therapeutics ... the human microbiome, announced today that Dr. ... R&D and Chief Scientific Officer, will be presenting ... and Chemotherapy (ICAAC). The presentation will highlight the ... mixture of bacterial spores derived from the human ...
(Date:8/28/2014)... 28, 2014 /PRNewswire-iReach/ -- Gateway Analytical announced today ... th Annual Global Pharma Manufacturing Summit in ... th . The Global Pharma Manufacturing Summit offers ... molecule and biologic pharmaceutical manufacturing. The conference is ... manufacturers face, such as the increasing pressure to ...
Breaking Medicine Technology:DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3
... Delcath Systems, Inc. (Nasdaq: DCTH ) today ... of Directors. Dr. Contag is a proven corporate executive with ... , (LOGO: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ... Cobalt Technologies, Inc. in 2006 and served as CEO. Prior ...
... & Alzheimer,s Disease , , ... today announced that its researchers have uncovered a new ... a potential target for developing novel therapeutics for intervention ... Institute,s Pancham Bakshi, Ph.D., is detailed in the ...
Cached Medicine Technology:Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 3Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease 2Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease 3
(Date:8/28/2014)... 28, 2014 Testimony began this ... a transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ )involving ... LLP reports. Court documents pending in the U.S. ... that the case was filed on behalf of ... surgeries, allegedly due to vaginal mesh complications associated ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 The Governor ... Microcredit Summit at a press conference; this event ... with the Ministry of Economy through the National Microenterprise ... from September 2nd to the 5th at the Convention ... , “It is a great responsibility for Yucatan to ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for EzCOI.com , is ... by walking 5,000 miles in a single year without ever ... thousands of individual stories of TrekDesk treadmill desk users across ... than the others. , Kirklyn has launched a website that ... range of 54,823 steps (presumably on an off day) to ...
(Date:8/28/2014)... August 28, 2014 Bank lending to the ... year, down by 0.13% in real terms, and continuing to ... new study by UHY, the international accountancy network. , UHY ... businesses in particular, the credit crunch lingers on. , UHY ... the last year have been wiped out by inflation. Over ...
(Date:8/28/2014)... of sleep not only puts teens at risk for poor ... researchers warn. The study authors analyzed data collected from ... 21. Nearly one-fifth of them got less than six hours ... this group was 20 percent more likely to be obese ... hours of sleep per night at age 16, the investigators ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2
... new study, a serious form of cancer that arises in ... normally serve as ‘scouts’ for the immune system. ... virus (EBV), which is usually kept under check by the ... control is lost and the transplanted organ may be rejected. ...
... characterized by pain and tenderness in the jaw muscles ... ,TMD is a problem for millions of Americans whose ... open-joint surgery. Whole system naturopathic care as a treatment ... of a new study involving 160 women in the ...
... a research conducted to study the link between work-related ... real or threatened violence at workplace run a major ... showed that the magnitude of the risk was in ... ,The findings of the study have been published ...
... of just a few puffs of cigarette that is capable ... that the amount of nicotine present in a single puff ... receptors and 3 puffs can occupy nearly 70% of these ... the receptors are filled up. But this feeling of satisfaction ...
... has now risen to 19 from 17. The official ... encephalitis was spreading rapidly.// ,Health officials in ... infections had emerged since July 13. Encephalitis causes the ... left untreated can be fatal. In China, health authorities ...
... The calories that contribute to ill health are loaded in ... consequentially off the lives of many // , who are ... with, the ideal thing would be to ensure the promotional ... that people are dished out the right information about healthy ...
Cached Medicine News:Health News:Deficient 'Scout Cells' Causes Cancer in Transplant Patients 2Health News:Deficient 'Scout Cells' Causes Cancer in Transplant Patients 3Health News:Naturopathic Care Proves Beneficial for TMD Pain 2Health News:Work-Related Violence Increases Risk Of Depression 2Health News:Imaging study affords renewed thrust on smoking cessation treatments 2Health News:Imaging study affords renewed thrust on smoking cessation treatments 3
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
... Control is designed to ... significant range of those ... during fertility or pregnancy ... hCG-Beta Subunit levels allow ...
... provides the clinical laboratory with the ... for monitoring immunoassay and therapeutic drug ... separate controls. Made from human serum ... suitable for most methods and is ...
Lyphochek Immunology Plus Control is an assayed control for monitoring chemistry procedures that test for autoimmune, anemic, malignant, hepatic and nephrotic-disease states. Available in two levels....
Medicine Products: